Search Results - "Villa, J. C."

Why do patellofemoral arthroplasties fail today? A systematic review by van der List, J.P, Chawla, H, Villa, J.C, Pearle, A.D

“…Abstract Background Historically poor results of patellofemoral arthroplasty (PFA) were reported in the setting of isolated patellofemoral osteoarthritis (OA)…”
Get full text

Simultaneous Determination of Erlotinib and its Metabolites in Human Urine and Serum Samples by High-Performance Liquid Chromatography by Rodríguez, J., Castañeda, G., Muñoz, L., Delgado, M. C., Lizcano, I., Villa, J. C., Lopez, R.

“…A simple and rapid reverse-phase high-performance liquid chromatographic method for the simultaneous separation and determination of erlotinib, an…”
Get full text

Current trends in the chemotherapy of colorectal cancer by Berciano-Guerrero, M A, Villa-Guzmán, J C, Acosta-Guerrero, R, Castañeda-Peñalvo, G, Rodríguez-Flores, J

“…The increase in the therapeutic arsenal in the last 20 years, has given rise to changes in treating colorectal cancer (CRC) with only pyrimidines to combine…”
Get more information

Validation of the International Metastatic Renal-Cell Carcinoma Database Consortium (IMDC) prognostic model for first-line pazopanib in metastatic renal carcinoma: the Spanish Oncologic Genitourinary Group (SOGUG) SPAZO study by Pérez-Valderrama, B., Arranz Arija, J.A., Rodríguez Sánchez, A., Pinto Marín, A., Borrega García, P., Castellano Gaunas, D.E., Rubio Romero, G., Maximiano Alonso, C., Villa Guzmán, J.C., Puertas Álvarez, J.L., Chirivella González, I., Méndez Vidal, M.J., Juan Fita, M.J., León-Mateos, L., Lázaro Quintela, M., García Domínguez, R., Jurado García, J.M., Vélez de Mendizábal, E., Lambea Sorrosal, J.J., García Carbonero, I., González del Alba, A., Suárez Rodríguez, C., Jiménez Gallego, P., Meana García, J.A., García Marrero, R.D., Gajate Borau, P., Santander Lobera, C., Molins Palau, C., López Brea, M., Fernández Parra, E.M., Reig Torras, O., Basterretxea Badiola, L., Vázquez Estévez, S., González Larriba, J.L.

“…Patients with metastatic renal carcinoma (mRCC) treated with first-line pazopanib were not included in the International Metastatic Renal Cell Carcinoma…”
Get full text

Early functional outcome after lateral UKA is sensitive to postoperative lower limb alignment by van der List, J. P., Chawla, H., Villa, J. C., Zuiderbaan, H. A., Pearle, A. D.

“…Purpose The predictive role of patient-specific characteristics and radiographic parameters on medial unicompartmental knee arthroplasty (UKA) outcomes is well…”
Get full text

Role of primary miRNA polymorphic variants in metastatic colon cancer patients treated with 5-fluorouracil and irinotecan by Boni, V, Zarate, R, Villa, J C, Bandrés, E, Gomez, M A, Maiello, E, Garcia-Foncillas, J, Aranda, E

“…MicroRNAs are non-coding RNAs that can block mRNA translation and influence mRNA stability. Recent evidence indicates that miRNA variations can affect drug…”
Get full text

P08.16 NECK PAIN DUE TO UNDETECTED METASTATIC LUNG ADENOCARCINOMA by Zaruma, C. L., Arregui, E., Gonzalez, L., Villa, J. C., Claramonte, M., Moreno, J. M. B.

“…PURPOSE: Computed tomography (CT) and magnetic resonance imaging (MRI) have contributed greatly to the ability to identify metastases in head and neck cancer…”
Get full text

OC54: Sonographic detection of umbilical cord cysts and associated findings during pregnancy; a 5‐year experience by Villa, J. C., Weiner, S.

Get full text

Optimizacion De La Quimioterapia En El Cáncer Epidermoide De Pulmon Avanzado, Antimetabolitos O Taxanos? by Espinosa, J, Villa, JC, Gomez, R, Sanchez, V, Lopez, R, Galan, R, Cano, JM, Murcia, M

Get full text

Eficacia De Docetaxel En Pacientes Con Cáncer De Prostata Resistente A Castraci"N En Primera Línea De Tratamiento by Villa, J C, Espinosa, J, Gomez, R, Sanchez, V, Lopez, R, Galan, R, Pineda, M D, Perez, M

Get full text

Efficacy of therapies after progression to up-front docetaxel (D) with androgen deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC) by Gajate Borau, P., Martin Marino, A., Gallegos Sancho, I., Villa Guzman, J.C., Velastegui, A., Alonso Gordoa, T., Castellano, D., Rubio Romero, G., Pinto Marin, A., Villalobos Leon, L., Maximiano Alonso, C., Sotelo-Lezama, M.J., Sereno Moyano, M., Rodríguez, J.F., Perezagua Marin, C., Ballesteros, J., Marrupe Gonzalez, D., Rodriguez Lajusticia, L., Tafalla García, J.J., Aguado, C.

Get full text

876P - Impact of germline mutations in homologous recombination (HR) genes on the response to Radium-223 for metastatic castration resistant prostate cancer (mCRPC) by Castro, E., Mejorada, R Lozano, Saez, M., De Giorgi, U.F.F., Aragón, I., Laorden, N Romero, De Velasco Oria de Rueda, G.A., Magraner, L., Pacheco, M.I., Puente, J., del Alba, A González, Garcia, P Borrega, Conteduca, V., Guzman, J C Villa, Parra, E Fernandez, Rodriguez-Vida, A., Colmenero, A Medina, Barrera, R Morales, Lorente, D., Hidalgo, D Olmos

“…Ra223 is a bone-seeking a-emitter targeted therapy that induces double-strand DNA breaks (DSBs). The HR pathway is used to accurately repair DSBs and a…”
Get full text

876PImpact of germline mutations in homologous recombination (HR) genes on the response to Radium-223 for metastatic castration resistant prostate cancer (mCRPC) by Castro, E, Mejorada, R Lozano, Saez, M, De Giorgi, U F F, Aragón, I, Laorden, N Romero, De Velasco Oria de Rueda, G A, Magraner, L, Pacheco, M I, Puente, J, del Alba, A González, Garcia, P Borrega, Conteduca, V, Guzman, J C Villa, Parra, E Fernandez, Rodriguez-Vida, A, Colmenero, A Medina, Barrera, R Morales, Lorente, D, Hidalgo, D Olmos

“…Abstract Background Ra223 is a bone-seeking a-emitter targeted therapy that induces double-strand DNA breaks (DSBs). The HR pathway is used to accurately…”
Get full text

880P - Impact of treatment sequence in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Data from the prospective PROREPAIR-B study by Cattrini, C., Laorden, N Romero, Castro, E., García-Carbonero, I., Piulats, J.M., Puente, J., Valderrama, B.P., Guzman, J C Villa, Billalabeitia, E Gonzalez, Barrera, R Morales, Mejorada, R Lozano, Luque, R., Ortega, E Martinez, Arija, J A Arranz, Diaz, E Gallardo, Marin, A Pinto, Casado, E Almagro, Vidal, M J Mendez, Hidalgo, D Olmos, Lorente, D.

“…Abiraterone (Abi), enzalutamide (Enz) and docetaxel (Doc) are all approved first-line (1L) treatment options for mCRPC. However, the optimal treatment sequence…”
Get full text

Impact of germline mutations in homologous recombination (HR) genes on the response to Radium-223 for metastatic castration resistant prostate cancer (mCRPC) by Castro, E., Mejorada, R Lozano, Saez, M., De Giorgi, U.F.F., Aragón, I., Laorden, N Romero, De Velasco Oria de Rueda, G.A., Magraner, L., Pacheco, M.I., Puente, J., del Alba, A González, Garcia, P Borrega, Conteduca, V., Guzman, J C Villa, Parra, E Fernandez, Rodriguez-Vida, A., Colmenero, A Medina, Barrera, R Morales, Lorente, D., Hidalgo, D Olmos

Get full text

880PImpact of treatment sequence in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Data from the prospective PROREPAIR-B study by Cattrini, C, Laorden, N Romero, Castro, E, García-Carbonero, I, Piulats, J M, Puente, J, Valderrama, B P, Guzman, J C Villa, Billalabeitia, E Gonzalez, Barrera, R Morales, Mejorada, R Lozano, Luque, R, Ortega, E Martinez, Arija, J A Arranz, Diaz, E Gallardo, Marin, A Pinto, Casado, E Almagro, Vidal, M J Mendez, Hidalgo, D Olmos, Lorente, D

“…Abstract Background Abiraterone (Abi), enzalutamide (Enz) and docetaxel (Doc) are all approved first-line (1L) treatment options for mCRPC. However, the…”
Get full text

Impact of treatment sequence in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Data from the prospective PROREPAIR-B study by Cattrini, C., Laorden, N Romero, Castro, E., García-Carbonero, I., Piulats, J.M., Puente, J., Valderrama, B.P., Guzman, J C Villa, Billalabeitia, E Gonzalez, Barrera, R Morales, Mejorada, R Lozano, Luque, R., Ortega, E Martinez, Arija, J A Arranz, Diaz, E Gallardo, Marin, A Pinto, Casado, E Almagro, Vidal, M J Mendez, Hidalgo, D Olmos, Lorente, D.

Get full text

TEMPORARY REMOVAL: PO-54: Preliminary evaluation of venous thromboembolic risk in patients with colorectal cancer from the CARTAGO study by Salgado, M, Molina, R, Vázquez, E Brozos, Martínez, E, Cillán, E, Fullana, T, Villa, J C, Lobo, M, Masvidal, M, Porta, R, Campos, B, Garicano, F, Pampols, M, Fernández, I, Font, C, Martínez, P, Gutiérrez, D, Horvath, E, Costa, A L, Malheiro, M, Arias, D, For The Cartago Study Group

“…The publisher regrets that this article has been temporarily removed. A replacement will appear as soon as possible in which the reason for the removal of the…”
Get full text

Manufacturing tracking system at Hewlett Packard Puerto Rico by Morales, Evelyn, Aguayo, Radamés, Villa, Juan C.

“…This paper describes the process used to design, develop and implement a custom made modular client-server on-line transaction processing and decision support…”
Get full text

HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies by Khalaf, D.J., Aragón, I.M., Annala, M., Lozano, R., Taavitsainen, S., Lorente, D., Finch, D.L., Romero-Laorden, N., Vergidis, J., Cendón, Y., Oja, C., Pacheco, M.I., Zulfiqar, M., Almagro, E., Arranz, J.Á., Billalabeitia, E.G., Borrega, P., Castro, E., Contreras, J.A., Domenech, M., Escribano, R., Fernández-Parra, E., Gallardo, E., García-Carbonero, I., García, R., Garde, J., González del Alba, A., González, B., Hernández, A., Hernando, S., Jiménez, P., Laínez, N., Lorente, D., Luque, R., Martínez, E., Medina, A., Méndez-Vidal, M.J., Montesa, A., Morales, R., Olmos David, Pérez-Gracia, J.L., Pérez-Valderrama, B., Pinto, Á., Piulats, J., Puente, J., Querol, R., Rodríguez-Vida, A., Romero-Laorden, N., Sáez, M.I., Vázquez, S., Vélez, E., Villa-Guzmán, J.C., Villatoro, R., Zambrana, C., Gleave, M.E., Wyatt, A.W., Olmos, D., Chi, K.N., Castro, E.

“…A common polymorphism (1245A>C) in the HSD3B1 gene is associated with increased de novo synthesis of androgens and worse outcomes in men treated with…”
Get full text